$KALA
KALA BIO, Inc.

2024 Q2 Form 10-Q Financial Statement

#000155837024008134 Filed on May 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $0.00
YoY Change -100.0%
Cost Of Revenue $0.00
YoY Change -100.0%
Gross Profit $0.00
YoY Change -100.0%
Gross Profit Margin
Selling, General & Admin $6.030M
YoY Change -77.65%
% of Gross Profit
Research & Development $5.317M $6.351M $4.036M
YoY Change 24.29% 57.36% -9.63%
% of Gross Profit
Depreciation & Amortization $61.00K $66.00K $77.00K
YoY Change -20.78% -14.29% -50.96%
% of Gross Profit
Operating Expenses $9.605M $11.93M $11.68M
YoY Change 0.06% 2.12% -63.81%
Operating Profit -$9.605M -$11.93M -$11.68M
YoY Change 0.06% 2.12% -62.21%
Interest Expense $1.455M $1.474M
YoY Change -1.29% -27.57%
% of Operating Profit
Other Income/Expense, Net $26.00K $124.0K -$2.772M
YoY Change -103.19% -104.47% 36.75%
Pretax Income -$14.46M
YoY Change -56.12%
Income Tax
% Of Pretax Income
Net Earnings -$9.579M -$11.81M -$14.46M
YoY Change -8.01% -18.32% -56.12%
Net Earnings / Revenue
Basic Earnings Per Share -$3.16 -$4.20 -$6.99
Diluted Earnings Per Share -$3.16 -$6.99
COMMON SHARES
Basic Shares Outstanding 2.816M 2.816M 2.025M
Diluted Shares Outstanding 3.030M 2.813M 2.069M

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $54.20M $48.48M $63.64M
YoY Change -8.42% -23.82% -9.3%
Cash & Equivalents $54.20M $48.48M $63.64M
Short-Term Investments
Other Short-Term Assets $1.200M $1.609M $7.313M
YoY Change -80.21% -78.0% 61.01%
Inventory
Prepaid Expenses
Receivables $117.0K $115.0K
Other Receivables $3.339M $280.0K
Total Short-Term Assets $58.85M $50.09M $71.34M
YoY Change -10.2% -29.8% -27.39%
LONG-TERM ASSETS
Property, Plant & Equipment $617.0K $714.0K $504.0K
YoY Change -3.14% 41.67% -81.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $273.0K $287.0K $372.0K
YoY Change -16.77% -22.85% -95.97%
Total Long-Term Assets $2.753M $2.946M $882.0K
YoY Change 185.28% 234.01% -93.38%
TOTAL ASSETS
Total Short-Term Assets $58.85M $50.09M $71.34M
Total Long-Term Assets $2.753M $2.946M $882.0K
Total Assets $61.61M $53.03M $72.23M
YoY Change -7.36% -26.57% -35.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $665.0K $732.0K $997.0K
YoY Change -12.5% -26.58% -83.97%
Accrued Expenses $3.924M $4.810M $5.076M
YoY Change -19.95% -5.24% -76.1%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $11.99M $5.992M $0.00
YoY Change
Total Short-Term Liabilities $19.19M $11.88M $10.27M
YoY Change 94.8% 15.72% -68.66%
LONG-TERM LIABILITIES
Long-Term Debt $22.83M $28.51M $33.27M
YoY Change -31.98% -14.3% -58.08%
Other Long-Term Liabilities $5.867M $5.983M $5.234M
YoY Change 4.99% 14.31% 10.45%
Total Long-Term Liabilities $28.70M $34.49M $38.50M
YoY Change -26.71% -10.41% -54.22%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.19M $11.88M $10.27M
Total Long-Term Liabilities $28.70M $34.49M $38.50M
Total Liabilities $47.89M $46.37M $48.77M
YoY Change -2.28% -4.91% -58.27%
SHAREHOLDERS EQUITY
Retained Earnings -$650.8M -$641.2M -$601.7M
YoY Change 6.33% 6.57% 4.58%
Common Stock $5.000K $3.000K $2.000K
YoY Change 66.67% 50.0% -97.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $13.72M $6.661M $23.46M
YoY Change
Total Liabilities & Shareholders Equity $61.61M $53.03M $72.23M
YoY Change -7.36% -26.57% -35.27%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$9.579M -$11.81M -$14.46M
YoY Change -8.01% -18.32% -56.12%
Depreciation, Depletion And Amortization $61.00K $66.00K $77.00K
YoY Change -20.78% -14.29% -50.96%
Cash From Operating Activities -$9.215M -$10.84M -$9.684M
YoY Change 21.33% 11.98% -59.8%
INVESTING ACTIVITIES
Capital Expenditures $36.00K $13.00K $108.0K
YoY Change -83.18% -87.96% -233.33%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities -$36.00K -$13.00K -$108.0K
YoY Change -99.64% -87.96% -97.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 14.97M 8.440M 2.858M
YoY Change 387.15% 195.31% 1755.84%
NET CHANGE
Cash From Operating Activities -9.215M -10.84M -9.684M
Cash From Investing Activities -36.00K -13.00K -108.0K
Cash From Financing Activities 14.97M 8.440M 2.858M
Net Change In Cash 5.719M -2.417M -6.934M
YoY Change -139.29% -65.14% -76.1%
FREE CASH FLOW
Cash From Operating Activities -$9.215M -$10.84M -$9.684M
Capital Expenditures $36.00K $13.00K $108.0K
Free Cash Flow -$9.251M -$10.86M -$9.792M
YoY Change 18.47% 10.88% -59.21%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001479419
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2759372
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2816454
CY2024Q1 kala Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2023 kala Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2024Q1 kala Fair Value Liabilities Level1 To Level2 Transfers Amount1
FairValueLiabilitiesLevel1ToLevel2TransfersAmount1
0
CY2023 kala Fair Value Liabilities Level1 To Level2 Transfers Amount1
FairValueLiabilitiesLevel1ToLevel2TransfersAmount1
0
CY2024Q1 kala Fair Value Liabilities Level2 To Level1 Transfers Amount1
FairValueLiabilitiesLevel2ToLevel1TransfersAmount1
0
CY2023 kala Fair Value Liabilities Level2 To Level1 Transfers Amount1
FairValueLiabilitiesLevel2ToLevel1TransfersAmount1
0
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-38150
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
KALA BIO, Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-0604595
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1167 Massachusetts Avenue
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Arlington
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02476
CY2024Q1 dei City Area Code
CityAreaCode
781
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
996-5252
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2024Q1 dei Trading Symbol
TradingSymbol
KALA
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2816454
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48478000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50895000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1609000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1975000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
50087000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
52870000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
714000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
753000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1945000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2025000
CY2024Q1 kala Restricted Cash And Other Assets Noncurrent
RestrictedCashAndOtherAssetsNoncurrent
287000
CY2023Q4 kala Restricted Cash And Other Assets Noncurrent
RestrictedCashAndOtherAssetsNoncurrent
301000
CY2024Q1 us-gaap Assets
Assets
53033000
CY2023Q4 us-gaap Assets
Assets
55949000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
732000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
919000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4810000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6018000
CY2023Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
1075000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
345000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
334000
CY2024Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
5992000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
11879000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8346000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1715000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1799000
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
28510000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
34190000
CY2024Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
4268000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
4110000
CY2024Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
34493000
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
40099000
CY2024Q1 us-gaap Liabilities
Liabilities
46372000
CY2023Q4 us-gaap Liabilities
Liabilities
48445000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2816454
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2759372
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
3000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
647874000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
636910000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-641216000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-629409000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
6661000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
7504000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
53033000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55949000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5422000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6030000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6351000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4036000
CY2023Q1 kala Gain Loss On Fair Value Re Measurement Of Deferred Purchase Consideration
GainLossOnFairValueReMeasurementOfDeferredPurchaseConsideration
230000
CY2024Q1 kala Gain Loss On Fair Value Re Measurement Of Contingent Consideration
GainLossOnFairValueReMeasurementOfContingentConsideration
-158000
CY2023Q1 kala Gain Loss On Fair Value Re Measurement Of Contingent Consideration
GainLossOnFairValueReMeasurementOfContingentConsideration
-1847000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
11931000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
11683000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-11931000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-11683000
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
504000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
675000
CY2024Q1 us-gaap Interest Expense
InterestExpense
1455000
CY2023Q1 us-gaap Interest Expense
InterestExpense
1474000
CY2024Q1 kala Income From Grants
IncomeFromGrants
1075000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1973000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
124000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2772000
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11807000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14455000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.20
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.99
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2813210
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2069186
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11807000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14455000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11807000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14455000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
7504000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
21000
CY2024Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
29000
CY2024Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
8538000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2376000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-11807000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
6661000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
18974000
CY2023Q1 kala Payments Of Stock Issuance Costs At Market Offering
PaymentsOfStockIssuanceCostsAtMarketOffering
384000
CY2023Q1 kala Stock Issued During Period Value New Issues At Market
StockIssuedDuringPeriodValueNewIssuesAtMarket
14893000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
6000
CY2023Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
365000
CY2023Q1 kala Asset Acquisition Contingent Milestone Consideration Equity Interest Issued Or Issuable
AssetAcquisitionContingentMilestoneConsiderationEquityInterestIssuedOrIssuable
2354000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1324000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-14455000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
23461000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-11807000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-14455000
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
66000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
77000
CY2024Q1 kala Non Cash Operating Lease
NonCashOperatingLease
80000
CY2023Q1 kala Non Cash Operating Lease
NonCashOperatingLease
10000
CY2023Q1 kala Gain Loss On Fair Value Re Measurement Of Deferred Purchase Consideration
GainLossOnFairValueReMeasurementOfDeferredPurchaseConsideration
230000
CY2024Q1 kala Gain Loss On Fair Value Re Measurement Of Contingent Consideration
GainLossOnFairValueReMeasurementOfContingentConsideration
-158000
CY2023Q1 kala Gain Loss On Fair Value Re Measurement Of Contingent Consideration
GainLossOnFairValueReMeasurementOfContingentConsideration
-1847000
CY2024Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
312000
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
329000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2376000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1324000
CY2024Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-17000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-80000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-378000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5470000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-2189000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-187000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1826000
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2164000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4489000
CY2024Q1 kala Increase Decrease In Lease And Other Liabilities Noncurrent
IncreaseDecreaseInLeaseAndOtherLiabilitiesNoncurrent
-73000
CY2023Q1 kala Increase Decrease In Lease And Other Liabilities Noncurrent
IncreaseDecreaseInLeaseAndOtherLiabilitiesNoncurrent
-10000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10844000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9684000
CY2024Q1 kala Payments To Acquire Property Plant And Equipment And Other Assets
PaymentsToAcquirePropertyPlantAndEquipmentAndOtherAssets
13000
CY2023Q1 kala Payments To Acquire Property Plant And Equipment And Other Assets
PaymentsToAcquirePropertyPlantAndEquipmentAndOtherAssets
108000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-108000
CY2024Q1 kala Payments Of Stock Issuance Costs Temporary Equity
PaymentsOfStockIssuanceCostsTemporaryEquity
62000
CY2024Q1 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
8538000
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14893000
CY2023Q1 kala Payment Of Principal On Venture Debt Facility
PaymentOfPrincipalOnVentureDebtFacility
10000000
CY2024Q1 kala Payment O Cash Portion Of Dosing Milestone
PaymentOCashPortionOfDosingMilestone
119000
CY2023Q1 kala Payment O Cash Portion Of Dosing Milestone
PaymentOCashPortionOfDosingMilestone
2041000
CY2024Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
21000
CY2023Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
6000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8440000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2858000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2417000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6934000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
50895000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
70745000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
48478000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
63811000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
48478000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
63811000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
175000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48478000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63636000
CY2023Q1 kala Capital Expenditures Incurred But Not Yet Paid Accounts Payable
CapitalExpendituresIncurredButNotYetPaidAccountsPayable
67000
CY2023Q1 kala Issuance Of Common Stock To Satisfy Deferred Purchase Consideration In Additional Paid In Capital
IssuanceOfCommonStockToSatisfyDeferredPurchaseConsiderationInAdditionalPaidInCapital
365000
CY2023Q1 kala Asset Acquisition Contingent Consideration Additional Paid In Capital
AssetAcquisitionContingentConsiderationAdditionalPaidInCapital
2354000
CY2024Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
29000
CY2024Q1 kala Payments Of Stock Issuance Costs Temporary Equity
PaymentsOfStockIssuanceCostsTemporaryEquity
62000
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
1144000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
1227000
CY2022Q3 kala Number Of Products Developed And Commercialized
NumberOfProductsDevelopedAndCommercialized
2
CY2022Q3 kala Disposal Group Including Discontinued Operation Number Of Milestone Payments Per Calendar Year
DisposalGroupIncludingDiscontinuedOperationNumberOfMilestonePaymentsPerCalendarYear
1
CY2022Q3 kala Disposal Group Including Discontinued Operation Number Of Milestone Payments Per Calendar Year
DisposalGroupIncludingDiscontinuedOperationNumberOfMilestonePaymentsPerCalendarYear
1
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11807000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14455000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10844000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9684000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-641216000
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
365000
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
0
CY2023Q1 kala Gain Loss On Fair Value Re Measurement Of Deferred Purchase Consideration
GainLossOnFairValueReMeasurementOfDeferredPurchaseConsideration
230000
CY2024Q1 kala Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2023 kala Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
149000
CY2023Q3 kala Royalty On Net Sales As Percent
RoyaltyOnNetSalesAsPercent
0.001
CY2023Q3 kala Royalty On Net Sales Based On Of Funds Utilized By Company
RoyaltyOnNetSalesBasedOnOfFundsUtilizedByCompany
1000000
CY2023Q3 kala Term Of Royalty From Date Of First Commercial Sale Of Such Product Service Or Approved Drug
TermOfRoyaltyFromDateOfFirstCommercialSaleOfSuchProductServiceOrApprovedDrug
P10Y
CY2024Q1 kala Accrued Revenue Reserves
AccruedRevenueReserves
1501000
CY2023Q4 kala Accrued Revenue Reserves
AccruedRevenueReserves
1659000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1271000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2616000
CY2024Q1 kala Development Costs Current
DevelopmentCostsCurrent
752000
CY2023Q4 kala Development Costs Current
DevelopmentCostsCurrent
837000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
710000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
515000
CY2024Q1 kala Accrued Contract Manufacturing
AccruedContractManufacturing
423000
CY2023Q4 kala Accrued Contract Manufacturing
AccruedContractManufacturing
11000
CY2024Q1 kala Other Accrued Expenses Current
OtherAccruedExpensesCurrent
153000
CY2023Q4 kala Other Accrued Expenses Current
OtherAccruedExpensesCurrent
380000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4810000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6018000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
10000
CY2024Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
8000
CY2023Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
20000
CY2024Q1 us-gaap Variable Lease Cost
VariableLeaseCost
60000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
6000
CY2024Q1 us-gaap Lease Cost
LeaseCost
217000
CY2023Q1 us-gaap Lease Cost
LeaseCost
36000
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
143000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
10000
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y4M24D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y8M12D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.131
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
438000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
601000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
622000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
644000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
440000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
685000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2060000
CY2024Q1 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.1720
CY2024Q1 us-gaap Long Term Debt
LongTermDebt
33957000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
33957000
CY2024Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
459000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
532000
CY2024Q1 kala Debt Instrument Exit Fees Of Total Principal Payments Value
DebtInstrumentExitFeesOfTotalPrincipalPaymentsValue
1004000
CY2023Q4 kala Debt Instrument Exit Fees Of Total Principal Payments Value
DebtInstrumentExitFeesOfTotalPrincipalPaymentsValue
765000
CY2024Q1 kala Adjusted Long Term Debt
AdjustedLongTermDebt
34502000
CY2023Q4 kala Adjusted Long Term Debt
AdjustedLongTermDebt
34190000
CY2024Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
5992000
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
28510000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
34190000
CY2024Q1 kala Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
4303
CY2023 kala Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
4303
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
75000000
CY2023Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
565974
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
75000000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
92062
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.081
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.082
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0398
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0398
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.86
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2376000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1324000
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11807000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14455000
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2813210
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2069186
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.20
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.99
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8308092
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5654811
CY2022Q4 kala Tax Credit Carryforward Amount Annual Limitation
TaxCreditCarryforwardAmountAnnualLimitation
222000
CY2024Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2024Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2023 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0

Files In Submission

Name View Source Status
0001558370-24-008134-index-headers.html Edgar Link pending
0001558370-24-008134-index.html Edgar Link pending
0001558370-24-008134.txt Edgar Link pending
0001558370-24-008134-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
kala-20240331.xsd Edgar Link pending
kala-20240331x10q.htm Edgar Link pending
kala-20240331xex31d1.htm Edgar Link pending
kala-20240331xex31d2.htm Edgar Link pending
kala-20240331xex32d1.htm Edgar Link pending
kala-20240331xex32d2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
kala-20240331_def.xml Edgar Link unprocessable
kala-20240331_lab.xml Edgar Link unprocessable
kala-20240331_pre.xml Edgar Link unprocessable
kala-20240331x10q_htm.xml Edgar Link completed
kala-20240331_cal.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending